Efficacy and Safety of Thymoquinone on Suppression of Tumor Growth in N-butyl-N-(4-hydroxybutyl)-Nitrosamine -Induced Bladder Cancer in Rats

Authors

  • Karmand Salih Hamaamin Qadir Department of Pharmacology and Toxicology-College of Pharmacy-University of Sulaimani-Sulaimani-Kurdistan Region-Iraq
  • Bushra Hassan Marouf Department of Pharmacology and Toxicology-College of Pharmacy-University of Sulaimani-Sulaimani-Kurdistan Region-Iraq

DOI:

https://doi.org/10.31351/vol32iss2pp150-161

Keywords:

Urothelial cancer, Therapeutic trial, BBN, Thymoquinone, Adverse effects

Abstract

Bladder cancer is one of the most common genitourinary malignancies worldwide, the therapeutic approaches for suppression of urothelial tumor and progression toward distant metastasis are not convincing. The present study was conducted to explore the curative effect and safety of THQ in N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) induced bladder cancer in rat.

Twenty-two male Wister albino rats were allocated into three group G1; served as control (n=6) received only the vehicle. G2: carcinogen group (n=6); animals had 0.05% BBN in drinking water for nine weeks. G3: Treatment group (n=10); THQ was administered at a dose of 50mg/Kg/day orally one week prior to the last exposure of BBN and continued till week 20. The bladder wall of all the animals was examined macroscopically for assessment of the number and the surface area of the lesions using Image J software program. Histopathological evaluation was also done for abnormal morphological alterations. Serum was analyzed for measurement of total oxidant status (TOS) and nuclear factor kappa- κB (NF-κB), transforming growth factor beta-1 (TGF-β1) as well as vascular endothelial growth factor (VEGF). Safety of THQ in respect of hematological, liver and renal function were also investigated. Bladder lesions in the THQ-treated group was reduced versus the carcinogen group. Histopathological findings in THQ-treated group demonstrated a significant improvement in the abnormal morphological growth in bladder, the TOS, NF-kβ, TGF-β, VEGF were mitigated non-significantly in the treatment group. The safety profile of THQ showed no significant deleterious effect on hematological, liver and renal function parameters with no signs of toxicity. THQ inhibited the development of neoplastic, preneoplastic transformations and it suppressed premalignant and malignant lesion formation in a rat model of bladder cancer. This might be due to antioxidant and anti-inflammatory properties of THQ. These data suggested that THQ may be effective and safe in ameliorating urinary bladder carcinogenesis.

Author Biography

  • Karmand Salih Hamaamin Qadir , Department of Pharmacology and Toxicology-College of Pharmacy-University of Sulaimani-Sulaimani-Kurdistan Region-Iraq

    Corresponding author is: Dr.Bushra Hassan Marouf 

    Email: [email protected] 

References

References

Klotz L, Brausi MA. World Urologic Oncology Federation Bladder Cancer Prevention Program: A global initiative. Urol Oncol Semin Orig Investig. 2015;33(1):25–9.

Alfred Witjes J, Lebret T, Compérat EM, Cowan NC, De Santis M, Bruins HM, et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017;71(3):462–75.

Williams SK, Hoenig DM, Ghavamian R, Soloway M. Intravesical therapy for bladder cancer. Expert Opin Pharmacother. 2010;11(6):947–58.

Lou K, Feng S, Zhang G, Zou J, Zou X. Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer. Front Oncol. 2022;12:879391.

Parada B, Reis F, Cerejo R, Garrido P, Sereno J, Xavier-Cunha M, et al. Omega-3 Fatty Acids Inhibit Tumor Growth in a Rat Model of Bladder Cancer. BioMed Res Int. 2013;2013:1–11.

Grubbs CJ, Lubet RA, Koki AT, Leahy KM, Masferrer JL, Steele VE, et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 2000;60(20):5599–602.

Mahmoud YK, Abdelrazek HMA. Cancer: Thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy. Biomed Pharmacother. 2019;115:108783.

Kohandel Z, Farkhondeh T, Aschner M, Samarghandian S. Anti-inflammatory effects of thymoquinone and its protective effects against several diseases. Biomed Pharmacother. 2021;138:111492.

Majdalawieh AF, Fayyad MW. Immunomodulatory and anti-inflammatory action of Nigella sativa and thymoquinone: A comprehensive review. Int Immunopharmacol. 2015;28(1):295–304.

Rajput S, Kumar BNP, Sarkar S, Das S, Azab B, Santhekadur PK, et al. Targeted Apoptotic Effects of Thymoquinone and Tamoxifen on XIAP Mediated Akt Regulation in Breast Cancer. Bauer JA, editor. PLoS ONE. 2013;8(4):e61342.

Gurung RL, Lim SN, Khaw AK, Soon JFF, Shenoy K, Mohamed Ali S, et al. Thymoquinone Induces Telomere Shortening, DNA Damage and Apoptosis in Human Glioblastoma Cells. Santos J, editor. PLoS ONE. 2010;5(8):e12124.

Ahmad A, Mishra RK, Vyawahare A, Kumar A, Rehman MU, Qamar W, et al. Thymoquinone (2-Isopropyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects. Saudi Pharm J. 2019;27(8):1113–26.

Almajali B, Al-Jamal HAN, Taib WRW, Ismail I, Johan MF, Doolaanea AA, et al. Thymoquinone, as a Novel Therapeutic Candidate of Cancers. Pharm Basel Switz. 2021 ;14(4):369.

Downloads

Published

2023-09-29